Critical Care & Emergencies (all articles)
Randomized trial: Convalescent plasma ineffective for patients hospitalized with Covid-19
23 Oct, 2020 | 09:15h | UTCEditorial: Convalescent plasma is ineffective for covid-19 – The BMJ
Commentary on Twitter
Just published @bmj_latest: A randomized trial of convalescent plasma for moderate covidhttps://t.co/dUvEMFSLHG
No benefit. It was underpowered to detect mortality reduction with 464 patients. A large RCT is needed to resolve the question, but these findings are not encouraging. pic.twitter.com/WGtz9IVSZe— Eric Topol (@EricTopol) October 23, 2020
Pro/con debate: Therapeutic anticoagulation in hospitalized patients with Covid-19 without established thromboembolism
23 Oct, 2020 | 09:12h | UTCAnticoagulation in Hospitalized Patients with Covid-19 – New England Journal of Medicine
Related editorial: Anticoagulation in COVID-19: It Is Time for High-Quality Evidence – Journal of the American College of Cardiology
Podcast: Deep vein thrombosis and pulmonary embolism
23 Oct, 2020 | 08:58h | UTC#238 DVT / PE Triple Distilled – The Curbsiders Internal Medicine Podcast
Best practices in managing cardiac arrest in the emergency department during the COVID-19 pandemic
22 Oct, 2020 | 09:44h | UTC
Randomized trial: Tocilizumab does not improve outcomes for patients hospitalized with Covid-19
22 Oct, 2020 | 09:42h | UTCEfficacy of Tocilizumab in Patients Hospitalized with Covid-19 – New England Journal of Medicine
New 2020 AHA Guidelines for CPR and emergency cardiovascular care in adults and children
22 Oct, 2020 | 09:47h | UTCHighlights: 2020 AHA Guidelines Update for CPR and ECC
Executive Summary: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care
New calculator predicts risk of hospital admission and mortality from coronavirus 19 in adults
22 Oct, 2020 | 09:37h | UTCSee calculator: QCovid® risk calculator
Commentary on Twitter
A new "living" high quality prediction model for #COVID19 risk for hospitalization and mortality: top 20% risk accounted for 94% of deaths; https://t.co/aPXRM2pHCq calculatorhttps://t.co/gdd8b3j33K @bmj_latest
by @AshClift @JuliaHCox @OxPrimaryCare and colleagues pic.twitter.com/s8TrWWECb0— Eric Topol (@EricTopol) October 21, 2020
Meta-analysis: Efficacy and safety of tranexamic acid in acute traumatic brain injury
22 Oct, 2020 | 09:31h | UTC
Commentary on Twitter
Tranexamic acid in acute TBI
➡️ 9 RCTs/14,747 pts
➡️ probably NO effect on mortality or disability
➡️ may decrease hematoma expansion on subsequent imaging (likely of minor importance to pts)
➡️ probably NO increased risk of adverse events#FOAMcc @yourICM https://t.co/sqn80NfNv4 pic.twitter.com/dMf8rYowC2— Intens Care Med (@yourICM) October 21, 2020
Studies offer little hope for Tocilizumab in treating COVID
21 Oct, 2020 | 09:27h | UTCStudies offer little hope for tocilizumab in treating COVID – CIDRAP
See studies: Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 – JAMA Internal Medicine AND Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial – JAMA Internal Medicine AND Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial – JAMA Internal Medicine
Commentary: expert reaction to three studies of Tocilizumab to treat COVID patients – Science Media Centre
Related study (preprint): Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia – medRxiv
Studies point to big drop in COVID-19 death rates
21 Oct, 2020 | 09:23h | UTCStudies Point To Big Drop In COVID-19 Death Rates – NPR
Podcast: Approach to shortness of breath
21 Oct, 2020 | 09:06h | UTC
Antimicrobial stewardship in ICUs during the COVID-19 pandemic: back to the 90s?
20 Oct, 2020 | 01:38h | UTC
Commentary on Twitter
Side effect of #COVID19 surge: ignoring well established strategies
➡️ limit ABTs exposure vs resistances: MV/long #ICU stay
➡️ avoid toxicity: antivirals/antibiotics can have severe adverse effects/interactions
➡️ high mortality: improving outcome crucial https://t.co/FN3LtKKlsr pic.twitter.com/7KGbIOH3Uf— Intens Care Med (@yourICM) October 17, 2020
Meta-analysis: The association of D-dimers with mortality, intensive care unit admission or ARDS in patients hospitalized with COVID-19
20 Oct, 2020 | 01:37h | UTC
Plastic surgery complications: A review for emergency clinicians
20 Oct, 2020 | 01:32h | UTC
Improving prone positioning for severe ARDS during the COVID-19 pandemic: An implementation mapping approach
18 Oct, 2020 | 23:17h | UTC
Commentary on Twitter
Improving Prone Positioning for Severe ARDS during the COVID-19 Pandemic: An Implementation Mapping Approach
✅ Just Accepted
? https://t.co/V8K3MUdSWU pic.twitter.com/wPJCp2mKaE— Annals of the ATS (@AnnalsATS) October 13, 2020
New studies show reduced prevalence and severity of SARS-CoV-2 infection in ABO blood group O
18 Oct, 2020 | 23:16h | UTCStudy 1: Reduced prevalence of SARS-CoV-2 infection in ABO blood group O – Blood Advances
Commentaries: People with blood type O may have lower risk of Covid-19 infection and severe illness, two new studies suggest – CNN AND Studies offer new evidence for possible link between blood type and COVID-19 susceptibility – American Society of Hematology
Acute Respiratory Distress Syndrome: Contemporary management and novel approaches during COVID-19
18 Oct, 2020 | 23:11h | UTCSource: Grupo UTI Clínica HCFMUSP
Commentary on Twitter
Review article in @_Anesthesiology showing a summary of 25 yr of ARDS intervention trials and contemporary management and novel approaches during COVID-19 ✅#ICU #CriticalCare #COVID__19 #ARDS https://t.co/MjLGgoTGy6 pic.twitter.com/wkVoOikhKQ
— Alice Blet, MD, PhD (@BletAlice) October 9, 2020
Cytokine elevation in severe and critical COVID-19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes
18 Oct, 2020 | 23:07h | UTC
Commentary on Twitter
The cytokine storm of severe #COVID19 and how it differs from ARDS, sepsis, and CAR-T cytokine release syndrome. Best review to date on this ★
Today @LancetRespirMed https://t.co/BOUjvIOWLi @danleisman @Poietic_Justice @IcahnMountSinai @CDMD62
? for pulling all this together pic.twitter.com/qZCPbrxvYU— Eric Topol (@EricTopol) October 16, 2020
SCCM International consensus conference on prediction and identification of long-term impairments after critical illness
18 Oct, 2020 | 22:59h | UTCSystematic review: Prediction Models for Physical, Cognitive, and Mental Health Impairments After Critical Illness: A Systematic Review and Critical Appraisal – Critical Care Medicine
Source: Grupo UTI Clínica HCFMUSP
Commentary on Twitter
"Prediction Models for Physical, Cognitive, and Mental Health Impairments After Critical Illness"
Open-access: https://t.co/zGz9Fb0Ku7
Companion to @SCCM's https://t.co/T9Pw40uD48
Led by @HainesKimberley @LizzyHib
Table 4 = awesome?(special thanks @GSCollins @MaartenvSmeden) pic.twitter.com/UyFPKOSHFM— Michael Harhay (@Michael_Harhay) October 15, 2020
Guideline: Management and prevention of anemia (acute bleeding excluded) in adult critical care patients
18 Oct, 2020 | 22:52h | UTC
Commentary on Twitter
Latest guidelines for anemia ?in critically ill patients by @SigLasocki published in @AccpmJ
? what threshold?
? how many RBCs?
?EPO as a substitute?➡️check the Full ? for the answers !https://t.co/sJIIbunwKB#CriticalCare #ICU #Anemia #MedTwitter #AnesthTwitter https://t.co/AMD5xZnWDr
— Alice Blet, MD, PhD (@BletAlice) October 15, 2020
[Preprint] WHO SOLIDARITY trial results published; Remdesivir, Hydroxychloroquine, Lopinavir, and Interferon do not improve outcomes in Covid-19
16 Oct, 2020 | 09:42h | UTCRepurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results – medRxiv
Commentary: Remdesivir and interferon fall flat in WHO’s megastudy of COVID-19 treatments – Science
Commentaries on Twitter
Results of the @WHO SOLIDARITY trial:
4 drugs tested in 11,266 patients with COVID in 405 hospitals in 30 countries:
– hydroxychloroquine
– lopinavir
– remdesevir
– interferonNo clear benefit of any of them on survival. https://t.co/ohtTAFaSnc pic.twitter.com/2fO9E8zs8h
— Martin Landray (@MartinLandray) October 16, 2020
This is blockbuster from @WHO: 'Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens have little or no effect on hospitalized COVID-19, as indicated by mortality, initiation of ventilation and duration of hospital stay. @medrxivpreprint https://t.co/aNGLzLL5uW pic.twitter.com/daOAMVW62u
— Harlan Krumholz (@hmkyale) October 15, 2020
Viewpoint: Sensible medicine—balancing intervention and inaction during the COVID-19 pandemic
16 Oct, 2020 | 09:38h | UTCSensible Medicine—Balancing Intervention and Inaction During the COVID-19 Pandemic – JAMA
Author interview: Sensible Medicine—Balancing Intervention and Inaction During the COVID-19 Pandemic
Commentary on Twitter
Has #COVID19 changed how you practice #medicine?
.
More Aggressive? Gentle? Humble? or Nihilistic?
.
Check out @JAMA_current elevating a discussion of Sensible Medicine.https://t.co/IfXVktCMJb @UPMC @UPMCnews @ErinMcCreary @PittCCM @PittTweet— Christopher Seymour (@seymoc) October 15, 2020
Cochrane living systematic review: Not enough evidence to recommend convalescent plasma for people with COVID‐19
16 Oct, 2020 | 09:34h | UTC
Commentary on Twitter
Just updated: @CochraneCollab living review investigates the use of convalescent plasma to treat people with COVID-19: https://t.co/Or5qmxki8H “We remain very uncertain about the effectiveness & safety of using convalescent plasma for people with #COVID19".
— The Cochrane Library (@CochraneLibrary) October 13, 2020
Study: Negative D-dimer safely rules out DVT as a stand-alone test
16 Oct, 2020 | 09:26h | UTCNegative D-dimer safely ruled out DVT as a stand-alone test – Blood Advances
Phase 3 trials show positive results for cefiderocol, but questions remain
15 Oct, 2020 | 09:07h | UTCPhase 3 trials show positive results for cefiderocol, but questions remain – CIDRAP